MN-ALPEGA
13.10.2020 16:17:08 CEST | Business Wire | Press release
Alpega, a global provider of cloud-based transportation management systems (TMS), today announced it has partnered with FourKites, a global leader in real-time and predictive supply chain visibility for shippers, carriers and logistics service providers, as part of its strategic value-adding partner ecosystem.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201013005635/en/
The partnership delivers integrated real-time, in-transit freight tracking across all modes and serves Alpega customers of all industries and verticals, enabling improved visibility and reduced supply chain costs.
“Successful end-to-end supply chain planning and execution requires real-time visibility and dependable predictive ETAs,” said Matt Elenjickal, CEO at FourKites. “Our predictive visibility platform leverages machine learning and advanced analytics to provide supply chain professionals with the real-time data needed to make informed, trusted decisions, and to remain agile in the face of any circumstance.”
The partnership combines the modular, scalable transportation management solution, Alpega TMS, with FourKites’ global, multimodal real-time transportation visibility platform. With the largest integrated carrier-base, this integration gives Alpega customers enhanced live shipment tracking and visibility data directly linked to the transportation order in Alpega TMS, providing actionable insights to drive operational efficiencies across supply chain operations.
“Our strategy when it comes to partnerships, is to work with the best to complement our TMS product portfolio,” said Todd DeLaughter, CEO at Alpega Group. “Our partnership with FourKites will provide our customers globally with the critical transportation technology and valuable timely data they need to create a competitive advantage. We look forward to the opportunities this strategic relationship will provide our joint customer base.”
Alpega TMS brings transparency and efficiency to all trading partners across the supply chain through one shared data set and collaborative platform for managing all transportation workflows. Moreover, through its partnership with FourKites, Alpega TMS provides enhanced supply chain visibility across all transportation modes within logistics networks.
Customers can benefit from the Alpega TMS collaborative platform for managing the end-to-end transportation process – from sourcing through settlement – across simple to complex logistics networks; while FourKites provides the end-to-end, real-time predictive visibility and analytics for improved customer service and delivery exception management.
Having pioneered the application of predictive visibility to various aspects of supply chain operations, FourKites’ network now includes more than 400 of the world’s top shippers and their broker and carrier partners - including 18 of the top-20 food and beverage companies and nine of the top-10 CPG companies. The platform tracks over 1 million loads and $100 billion in freight at any given time. FourKites leverages data science breakthroughs and machine learning to provide real-time tracking of shipments across all modes of transportation in 80+ countries, and calculates the industry’s most accurate ETAs. In 2020, FourKites expanded visibility into the yard, creating a new category of software that gives enterprises the ability to proactively manage all their facilities based on real-time in-transit and in-yard freight data and analytics.
“We are happy to have FourKites as a global partner,” said Mark Mc Arthur, Managing Director of Alpega North America. “Their leadership in the real-time visibility platform and digital yard management space will add tangible value to our customer’s businesses. We look forward to working with them.”
About FourKites
FourKites is the largest predictive supply chain visibility platform, delivering real-time visibility and predictive analytics for the broadest network of Global 1000 companies and third-party logistics firms. With the largest repository of supply chain data on the planet, FourKites’ network spans millions of GPS/ELD devices. Using a proprietary algorithm to calculate shipment arrival times, FourKites enables customers to lower operating costs, improve on-time performance and strengthen end-customer relationships. The platform is optimized for mobile devices and equipped with market-leading end-to-end security. For more information, visit http://www.fourkites.com
.
About Alpega
Alpega is a global provider of cloud-based transportation management systems (TMS). Alpega enables shippers, their customers, logistics service providers and carriers the ability to collaboratively manage end-2-end transportation activities for increased visibility, capacity and reduced freight spend. By streamlining transportation sourcing, planning, execution, settlement and analytics, Alpega solutions transform local and global supply chains into collaborative ecosystems - bringing transparency and efficiency to all trading partners involved. Alpega’s 200,000+ user community are present in 80 countries worldwide. For more information, visit na.alpegagroup.com
for North America; and alpegagroup.com
for Europe.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201013005635/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
